ALEMBIC
|
ALEMBIC Last 5 Year Financial Ratios History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 10.46 | 7.42 | 8.65 | 13.35 | 12.82 |
CEPS(Rs) | 3.92 | 3.40 | 3.55 | 0.69 | 3.75 |
DPS(Rs) | 2.40 | 2.20 | 1.80 | 0.20 | 0.60 |
Book NAV/Share(Rs) | 85.11 | 80.93 | 97.23 | 89.45 | 55.22 |
Tax Rate(%) | 9.56 | 7.12 | 11.92 | 18.78 | 0.14 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 36.11 | 31.70 | 17.81 | 14.18 | 4.25 |
EBIT Margin(%) | 65.91 | 68.58 | 125.61 | 23.67 | 126.41 |
Pre Tax Margin(%) | 65.20 | 68.21 | 125.11 | 23.18 | 126.02 |
PAT Margin (%) | 58.97 | 63.36 | 110.20 | 18.83 | 125.85 |
Cash Profit Margin (%) | 63.95 | 68.64 | 116.42 | 24.19 | 130.21 |
Performance Ratios | |||||
ROA(%) | 4.09 | 3.33 | 3.42 | 0.71 | 6.80 |
ROE(%) | 4.36 | 3.52 | 3.60 | 0.75 | 7.08 |
ROCE(%) | 4.86 | 3.82 | 4.10 | 0.94 | 7.12 |
Asset Turnover(x) | 0.07 | 0.05 | 0.03 | 0.04 | 0.05 |
Sales/Fixed Asset(x) | 1.04 | 0.84 | 0.52 | 0.50 | 0.43 |
Working Capital/Sales(x) | 3.35 | 1.44 | 1.04 | 1.72 | 0.63 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.96 | 1.19 | 1.92 | 2.01 | 2.35 |
Receivable days | 50.07 | 55.47 | 67.74 | 56.58 | 55.52 |
Inventory Days | 210.00 | 251.69 | 329.34 | 222.67 | 174.64 |
Payable days | 180.44 | 162.67 | 299.17 | 252.73 | 565.67 |
Valuation Parameters | |||||
PER(x) | 8.00 | 7.99 | 8.37 | 7.70 | 2.79 |
PCE(x) | 21.33 | 17.43 | 20.40 | 148.53 | 9.52 |
Price/Book(x) | 0.98 | 0.73 | 0.74 | 1.15 | 0.65 |
Yield(%) | 2.87 | 3.71 | 2.49 | 0.19 | 1.68 |
EV/Net Sales(x) | 13.68 | 11.95 | 23.73 | 35.84 | 11.60 |
EV/Core EBITDA(x) | 19.30 | 14.54 | 18.00 | 123.44 | 8.87 |
EV/EBIT(x) | 20.76 | 17.43 | 18.89 | 151.39 | 9.18 |
EV/CE(x) | 0.98 | 0.73 | 0.71 | 1.09 | 0.58 |
M Cap / Sales | 13.64 | 11.97 | 23.75 | 35.92 | 12.40 |
Growth Ratio | |||||
Net Sales Growth(%) | 23.77 | 62.68 | 6.39 | -0.55 | -40.29 |
Core EBITDA Growth(%) | 6.73 | 1.44 | 383.10 | -77.92 | 103.46 |
EBIT Growth(%) | 18.94 | -11.18 | 464.53 | -81.38 | 108.18 |
PAT Growth(%) | 15.19 | -6.47 | 522.73 | -85.12 | 126.45 |
EPS Growth(%) | 40.90 | -14.15 | -35.23 | 4.17 | 54.44 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | - | - | - | - | - |
Current Ratio(x) | 1.49 | 1.99 | 2.12 | 1.72 | 3.56 |
Quick Ratio(x) | 0.53 | 1.00 | 0.83 | 0.80 | 2.78 |
Interest Cover(x) | 93.63 | 187.54 | 252.50 | 48.08 | 324.49 |
Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of ALEMBIC
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
ALEMBIC | ₹3,338.4 Cr | -4.3% | -0.9% | 43% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹451,603.0 Cr | 3.7% | 8.5% | 49.4% | Stock Analytics | |
DIVIS LABORATORIES | ₹160,862.0 Cr | 3.6% | 1.8% | 52.1% | Stock Analytics | |
CIPLA | ₹122,810.0 Cr | 3% | 1.9% | 20.9% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹114,946.0 Cr | 2.7% | 15.5% | 23.2% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹96,377.1 Cr | -1.6% | 1% | 43.9% | Stock Analytics |
ALEMBIC Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
ALEMBIC | -4.3% |
-0.9% |
43% |
SENSEX | 0.3% |
-2.5% |
10% |
You may also like the below Video Courses